Literature DB >> 12581896

Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma.

Gudrun Schleiermacher1, Isabelle Janoueix-Lerosey, Valérie Combaret, Josette Derré, Jérome Couturier, Alain Aurias, Olivier Delattre.   

Abstract

Neuroblastoma is characterized by several distinct genetic alterations including MYCN amplification, chromosome 1p deletion and gain of chromosome 17. Although these alterations are thought to play a crucial role in oncogenesis, to date little is known about their underlying mechanisms. In order to more precisely document these genetic alterations, we have performed a combined study of 27 neuroblastoma cell lines using 24-color karyotyping (24-CK) and comparative genomic hybridization (CGH). 24-CK detected balanced translocations in 13 cases with recurrent involvement of chromosome 8. More importantly, 144 nonreciprocal translocations were observed in the 27 cell lines, with chromosome 1 as the most frequent recipient and chromosome 17 the most frequent donor. Each cell line exhibited at least one unbalanced translocation involving 17q, with 14 cell lines demonstrating more than one such translocation. Other recurrent alterations were amplification of the 2p24 chromosome region, which encodes the MYCN oncogene, losses of 1p, 3p and 11q, and gains of 1q and 7. In most cases, CGH profiles were directly linked to the presence of unbalanced translocations with gain of the donor fragment and loss of the replaced region on the recipient chromosome. Strikingly, over 60% of the chromosome breakpoints mapped to early replicating chromosome bands, which represent around 13% of the genome. Altogether these data suggest that neuroblastoma is characterized by rearrangements that predominantly involve chromosome fragments replicating early in the S-phase.

Entities:  

Mesh:

Year:  2003        PMID: 12581896     DOI: 10.1016/s0165-4608(02)00644-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  14 in total

1.  COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.

Authors:  Emma Bell; Frida Ponthan; Claire Whitworth; Deborah A Tweddle; John Lunec; Christopher P F Redfern
Journal:  Clin Exp Metastasis       Date:  2014-05-25       Impact factor: 5.150

2.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

3.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

Authors:  Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

4.  Highly conserved regimes of neighbor-base-dependent mutation generated the background primary-structural heterogeneities along vertebrate chromosomes.

Authors:  Marcos A Antezana; I King Jordan
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

5.  Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.

Authors:  Valentina Boeva; Caroline Louis-Brennetot; Agathe Peltier; Simon Durand; Cécile Pierre-Eugène; Virginie Raynal; Heather C Etchevers; Sophie Thomas; Alban Lermine; Estelle Daudigeos-Dubus; Birgit Geoerger; Martin F Orth; Thomas G P Grünewald; Elise Diaz; Bertrand Ducos; Didier Surdez; Angel M Carcaboso; Irina Medvedeva; Thomas Deller; Valérie Combaret; Eve Lapouble; Gaelle Pierron; Sandrine Grossetête-Lalami; Sylvain Baulande; Gudrun Schleiermacher; Emmanuel Barillot; Hermann Rohrer; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Nat Genet       Date:  2017-07-24       Impact factor: 38.330

6.  Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11.

Authors:  Katleen De Preter; Jo Vandesompele; Björn Menten; Philippa Carr; Heike Fiegler; Anders Edsjö; Nigel P Carter; Nurten Yigit; Wim Waelput; Nadine Van Roy; Scott Bader; Sven Påhlman; Frank Speleman
Journal:  BMC Genomics       Date:  2005-07-06       Impact factor: 3.969

7.  cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.

Authors:  Qing-Rong Chen; Sven Bilke; Jun S Wei; Craig C Whiteford; Nicola Cenacchi; Alexei L Krasnoselsky; Braden T Greer; Chang-Gue Son; Frank Westermann; Frank Berthold; Manfred Schwab; Daniel Catchpoole; Javed Khan
Journal:  BMC Genomics       Date:  2004-09-20       Impact factor: 3.969

8.  Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

Authors:  Kamaraj Sattu; Falko Hochgräfe; Jianmin Wu; Ganesh Umapathy; Christina Schönherr; Kristina Ruuth; Damini Chand; Barbara Witek; James Fuchs; Pui-Kai Li; Fredrik Hugosson; Roger J Daly; Ruth H Palmer; Bengt Hallberg
Journal:  FEBS J       Date:  2013-08-22       Impact factor: 5.542

9.  Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis.

Authors:  Valentina Boeva; Stéphanie Jouannet; Romain Daveau; Valérie Combaret; Cécile Pierre-Eugène; Alex Cazes; Caroline Louis-Brennetot; Gudrun Schleiermacher; Sandrine Ferrand; Gaëlle Pierron; Alban Lermine; Thomas Rio Frio; Virginie Raynal; Gilles Vassal; Emmanuel Barillot; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

10.  No evidence for involvement of SDHD in neuroblastoma pathogenesis.

Authors:  Katleen De Preter; Jo Vandesompele; Jasmien Hoebeeck; Caroline Vandenbroecke; Jöel Smet; Annick Nuyts; Geneviève Laureys; Valérie Combaret; Nadine Van Roy; Frank Roels; Rudy Van Coster; Marleen Praet; Anne De Paepe; Frank Speleman
Journal:  BMC Cancer       Date:  2004-08-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.